DCTH

Delcath Systems, Inc. is a pioneering interventional oncology company focused on transforming treatment paradigms for patients suffering from primary and metastatic liver cancers in the U.S. and Europe. Headquartered in New York, the firm utilizes its proprietary technologies to facilitate targeted delivery of cancer therapies directly to the liver, optimizing therapeutic efficacy while reducing systemic toxicity. With a robust pipeline of clinical programs and a commitment to expanding its market presence, Delcath is strategically positioned to address critical unmet needs within the oncology sector, driving innovation and improving patient outcomes.